About
Kenai Therapeutics is a clinical-stage biotechnology company developing off-the-shelf dopamine neuron replacement cell therapies and gene-modified medicines to treat and potentially cure neurological conditions such as Parkinson’s disease.
Explore Kenai Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.